Title: TERUMO BCT SPECTRA OPTIA APHERESIS SYSTEM
NAICS Code: 334516: Analytical Laboratory Instrument Manufacturing6 1,000
Product Service Code: 6640: Laboratory Equipment and Supplies.
Place of Performance: Bethesda, MD 20892
POTS: 25-005554
Description
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued, and quotations will not be requested. The National Institutes of Health (NIH), Clinical Center, Office of Purchasing and Contracts on behalf of the The Department of Transfusion Medicine, serves as the clinical laboratory of the Clinical Research Center intends to award a fixed priced sole source purchase order to Terumo BCT located in West Collins Avenue Lakewood, CO 80215 USA to Supplies needed Apheresis System. The proposed devices are critical platform for blood cell collection, therapeutic apheresis, and cell.
Description:
Product Quantity. Catalog #
SPECTRA OPTIA APHERES 2 61000
IDL Filler 2 703399003
KIT, LANG, OPTIA, US, ENUS 2 705244003
Installation Kit 2 610130000
Power Cord Style B, Medical Grade 2 701271000
Terumo BCT is the Original Equipment Manufacturer of Spectra Optia Apheresis System. The Apheresis system preforms critical function on platform for blood cell collection, therapeutic apheresis, and cell processing at the Department of Transfusion Medicine of Clinical Center. The Spectra Optia Apheresis System is an industry-leading therapeutic apheresis, cell processing, and cell collection platform that allows operators to spend more time focusing on patient care. This advanced system uses continuous-flow centrifugation and optical detection technology, providing operators the ability to perform a wide variety of apheresis procedures on a single platform. The current equipment has reached the end of its operational lifecycle, with escalating maintenance costs and the risk of disruptive downtime threatening patient care services. Replacing the devices will ensure uninterrupted, reliable medical procedures, reduce long-term expenses, and maintain the highest standards of patient care. Therefore, Terumo BCT is the only source capable of fulfilling this requirement.
This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.
Interested Parties:
Interested parties capable of providing the same or similar products or services described in this notice may submit a capability statement outlining their capability to perform the described work. Capability Statements must be received within the time set forth in this synopsis to be considered by the Government. The determination to compete this proposed contract based on responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.
Comments:
Comments to this announcement, referencing this posting number on the email subject line, may be submitted to the CC, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, electronically to the attention of Emeka Onyejekwe, Contract Specialist, [email protected] by the due date May 05th, 2025, 12:00 pm EST and time marked in this notice. No phone calls will be accepted.